封面
市場調查報告書
商品編碼
1138278

2022-2029 年全球靜脈-靜脈體外循環 (v-v ECLS) 市場

Global Veno-Venous Extracorporeal Life Support (VV ECLS) Devices Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球靜脈-靜脈體外循環 (v-v ECLS) 市場受到多種因素的推動,例如心肺和呼吸系統疾病的患病率不斷提高、對心肺疾病的認識不斷提高、對心肺監測和治療系統的需求不斷增加。促進因素推動了增長.

心肺和呼吸系統疾病的日益流行正在推動全球市場的增長。

心肺疾病是指影響心臟和肺部的多種疾病,心肺疾病一般有心血管疾病和慢性阻塞性肺疾病(COPD)兩種,其患病率的上升是推動全球市場的增長。例如,根據英國心臟基金會的數據,2020 年將有大約 168,319 人死於心血管疾病。由於人口老齡化、可支配收入增加、生活方式改變和吸煙等多種因素,心肺疾病呈上升趨勢。10億人,預計到2050年將達到21億人。然而,煙草消費每年導致全球超過 800 萬人死亡,其中 700 萬人歸因於直接使用,120 萬人歸因於非吸煙者接觸二手煙。我在這裡。靜脈-靜脈體外循環 (v-v ECLS) 有助於通過適當的干預將患者的身體維持在正常水平。這些裝置在新生兒期顯示出良好的效果,有助於維持急性呼吸窘迫綜合徵 (ARDS) 和單心室生理。截至 2022 年 4 月,國際上有 172,853 名患者使用外部生命支持系統 (ECLS),其中包括 46,698 名新生兒、93,091 名成人和 33,064 名年齡較大的兒童。 2021年註冊ELSO中心的數量將達到543個,2021年ECLS的使用量將達到17,777個,在過去幾年中呈現急劇增長。

並發症和熟練專業人員的短缺正在阻礙全球靜脈-靜脈體外循環 (v-v ECLS) 市場的發展。

但是,與外部生命支持設備相關的一些並發症,例如出血、感染和技術故障,加上設備的高成本和缺乏熟練的專業人員,阻礙了市場的增長。

COVID-19 影響分析

由於 COVID-19 是一種導致呼吸困難的嚴重急性呼吸綜合徵,而體外膜肺氧合 (ECMO) 是一種為肺部提供長期呼吸支持的體外技術,COVID-19 的爆發導致對體外膜肺氧合(ECMO),對全球市場的增長產生了積極影響。例如,根據體外生命支持組織的數據,13,988 名確診的 COVID-19 患者至少在 90 天前開始了 ECMO。

全球靜脈-靜脈體外循環 (v-v ECLS) 市場報告將提供對大約 40 多個市場數據表、45 多個數字和 200 多頁(大約)的訪問。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 心腦血管疾病增加
      • 老年人口增加
      • 市場策略
    • 約束因素
      • 缺乏熟練的專業人員
      • 相關並發症
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 單心室裝置
  • 腦室裝置

第 8 章最終用戶

  • 醫院
  • 醫務室
  • 門診手術中心 (ASC)
  • 其他

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 11 章公司簡介

  • Medtronic, Plc
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • MAQUET Holding B. V. & Co. KG(Getinge Group),
  • Microport Scientific Corporation,
  • Sorin Group,
  • Nipro Medical Corporation,
  • Terumo Cardiovascular Systems Corporation,
  • MedosMedizintechnik AG

第12章 DataM

簡介目錄
Product Code: DMMD2108

Market Overview

Veno-Venous Extracorporeal Life Support (VV ECLS) Devices Market is expected to grow at a high CAGR of 9.4% during the forecasting period (2022-2029).

Extracorporeal life support (ECLS), also known as extracorporeal membrane oxygenation (ECMO), is an extracorporeal technique that provides prolonged cardiac and respiratory support to the heart and lungs which are not able to provide an adequate amount of gas exchange or perfusion to sustain life. The technology for ECLS is derived from cardiopulmonary bypass, which provides shorter-term support with arrested native circulation.

In venovenous (VV) ECLS, cannulae are placed in the right common femoral vein for drainage and the right internal jugular vein for infusion. Alternatively, a dual-lumen catheter is inserted into the right internal jugular vein, draining blood from the superior and inferior vena cavae and returning it to the right atrium.

Market Dynamics

The global veno-venous extracorporeal life support (VV ECLS) devices market is growing due to several driving factors such as increasing the prevalence of cardiopulmonary disease & respiratory disorders and, raising awareness of the cardiopulmonary disease and increasing demand for cardiopulmonary monitoring and treatment system.

The increasing prevalence of cardiopulmonary disease & respiratory disorders is propelling the global market growth.

Cardiopulmonary disease refers to a range of diseases that affect the heart and the lungs, there are two common types of cardiopulmonary conditions: cardiovascular disease; and chronic obstructive pulmonary disorder (COPD), and their growing prevalence is driving the global market growth. For instance, according to the British Heart Foundation, around 168,319 people died from CVD in 2020. Cardiopulmonary diseases are rising due to several factors, such as the growing geriatric population, rising disposable income, changing lifestyles, smoking, and others; for instance, according to the world health organization, in 2020, there were 1 billion people aged 60 and above in 2020 and is estimated that by 2050 it will reach 2.1 billion. However, tobacco consumption is the cause behind over 8 million deaths each year globally, of which 7 million are due to direct use, and 1.2 million are because of non-smokers exposed to secondhand smoke. The Venovenous extracorporeal life support (VV ECLS) devices help the patients maintain the body to a normal level through appropriate intervention. These devices have shown favorable neonatal results and help maintain acute respiratory distress syndrome (ARDS) and single-ventricle physiology. As of April 2022, 172,853 patients had been placed on extracorporeal life support (ECLS) internationally, of which 46,698 were neonates, 93,091 were adults, and 33,064 were older children. The number of registered ELSO centers and their yearly use of ECLS increased precipitously in the last few years to 543 centers in 2021 and 17777 runs in 2021, respectively.

The complications and lack of skilled professionals hinder the global Veno-venous extracorporeal life support (VV ECLS) device market growth.

However, several complications associated with extracorporeal life support devices, such as bleeding, infections, and technical failures, coupled with the high cost of the devices and lack of skilled professionals, hinder the market's growth.

COVID-19 Impact Analysis

As COVID-19 is a severe acute respiratory syndrome that causes difficulty in breathing, and since extracorporeal membrane oxygenation (ECMO) is an extracorporeal technique that provides prolonged respiratory support to the lungs, the outburst of COVID-19 caused a rise in the demand for the extracorporeal membrane oxygenation (ECMO) therefore positively impacting the global market growth. For instance, according to the Extracorporeal Life Support Organization, 13988 Confirmed COVID-19 patients initiated ECMO at least 90 days ago.

Segment Analysis

Veno-venous extracorporeal life support (VV ECLS) devices are predicted to have a high demand during the forecast period (2022-2029).

The veno-venous extracorporeal life support (VV ECLS) devices market is segmented into the hindergle-ventricular device and biventricular device by product type. Among these, the venovenous extracorporeal life support (VV ECLS) devices in single-ventricle patients have shown increased market share in 2021 and are estimated to grow significantly over the forecast period. Single-site dual-lumen cannulas are used in infants, children, and adults. This approach incorporates drainage and reinfusion lumens into one unit inserted through the right internal jugular vein (RIJV). However, the venovenous ECLS has a substantial risk in patients with single-ventricle disorder due to coronary, pulmonary, and cerebral circulations. Biventricular devices supported with a paracorporeal pulsatile device are an efficient bridge to recovery for patients with fulminant myocarditis-related cardiogenic shock.

Geographical Analysis

North America is predicted to command the global Veno-venous Extracorporeal Life Support (VV ECLS) Devices market.

North America is dominating the global veno-venous extracorporeal life support (VV ECLS) devices market, accounting for the largest market share in 2021, owing to the rising prevalence of cardiopulmonary diseases, growing aging population, and active intervention by the government like the "Million Hearts" initiative by U.S. government to spread awareness about risk associated with cardiopulmonary diseases. According to the CDC, every 34 seconds, a U.S. American dies because of cardiovascular disease; in 2020, 697,000 American deaths were caused by cardiovascular disease. The North American VV ECLS market is expected to grow rapidly over the forecast period, owing to the rising demand for new innovative products. Terumo Cardiovascular Systems Corporation has refined existing technology while manufacturing CAPIOX FX Oxygenator.

Competitive Landscape

The veno-venous extracorporeal life support (VV ECLS) devices market is competitive with few major players. Some of the major players in the global veno-venous extracorporeal life support (VV ECLS) devices market include Medtronic, Plc, MAQUET Holding B. V. & Co. KG (Getinge Group), Microport Scientific Corporation, Sorin Group, Nipro Medical Corporation, Terumo Cardiovascular Systems Corporation, MedosMedizintechnik AG, among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the veno-venous extracorporeal life support (VV ECLS) devices market globally. For instance, on July 12, 2022, Medtronic announced a co-promotion agreement with CathWorks, with an acquisition plan. Also, on 02 Jun 2022, Hemovent achieved MDSAP Certificate for the United States and Canada.

Medtronic, Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The product portfolio of Medtronic, Plc. The product portfolio for veno-venous extracorporeal life support (VV ECLS) devices contains Nautilus Smart ECMO Module, Nautilus ECMO Oxygenator, Crescent RA Jugular Dual Lumen Catheter and Crescent Jugular Dual Lumen Catheter.

The global veno-venous extracorporeal life support (VV ECLS) devices market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Prevalence of Cardio Vascular Diseases
      • 4.1.1.2. Growing Geriatric Population
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Skilled Professional
      • 4.1.2.2. Associated Complication
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Single-ventricular device
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Biventricular device

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 8.1.2. Market Attractiveness Index, By End User Segment
  • 8.2. Hospitals
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Clinics
  • 8.4. Ambulatory Surgical Centers (ASCs)
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Company Profiles

  • 11.1. Medtronic, Plc
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. MAQUET Holding B. V. & Co. KG (Getinge Group),
  • 11.3. Microport Scientific Corporation,
  • 11.4. Sorin Group,
  • 11.5. Nipro Medical Corporation,
  • 11.6. Terumo Cardiovascular Systems Corporation,
  • 11.7. MedosMedizintechnik AG

LIST NOT EXHAUSTIVE

12. DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us